OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
-14.68%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$463M
AUM Growth
+$463M
(-10%)
Cap. Flow
+$48.7M
Cap. Flow
% of AUM
10.53%
Top 10 Holdings %
Top 10 Hldgs %
79.39%
Holding
31
New
3
Increased
8
Reduced
6
Closed
7
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$16.2M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$14M |
| 3 |
Arcus Biosciences
RCUS
|
$12.5M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$10.5M |
| 5 |
Gossamer Bio
GOSS
|
$9.11M |
Top Sells
| 1 |
Cytek Biosciences
CTKB
|
$6.53M |
| 2 |
Cardiff Oncology
CRDF
|
$5.91M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$4.53M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$3.96M |
| 5 |
Monte Rosa Therapeutics
GLUE
|
$3.06M |
Sector Composition
| 1 | Healthcare | 98.92% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $119M | 25.7% | 2,340,059 +319,148 | +16% | +$16.2M |
|
|
2
Arcus Biosciences
RCUS
$1.13B
| $78.6M | 16.99% | 2,489,974 +394,743 | +19% | +$12.5M |
|
3
Celldex Therapeutics
CLDX
$1.47B
| $25.9M | 5.61% | 761,398 | – | – |
|
4
4D Molecular Therapeutics
FDMT
$288M
| $23.7M | 5.12% | 1,566,895 +15,825 | +1% | +$239K |
|
5
BridgeBio Pharma
BBIO
$9.89B
| $23M | 4.98% | 2,267,486 +500,000 | +28% | +$5.08M |
|
|
6
Gossamer Bio
GOSS
$562M
| $22.2M | 4.81% | 2,563,138 +1,050,000 | +69% | +$9.11M |
|
|
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $22.2M | 4.8% | 1,356,250 +856,250 | +171% | +$14M |
|
8
Keros Therapeutics
KROS
$618M
| $18.5M | 4% | 340,214 | – | – |
|
9
Stoke Therapeutics
STOK
$1.08B
| $17.1M | 3.7% | 813,456 +29,687 | +4% | +$625K |
|
|
IMAB
10
I-MAB
IMAB
$340M
| $17M | 3.69% | 1,049,691 | – | – |
|
11
iTeos Therapeutics
ITOS
| $14.5M | 3.14% | 450,776 | – | – |
|
12
Vera Therapeutics
VERA
$1.38B
| $13.5M | 2.92% | 575,000 -95,940 | -14% | -$2.25M |
|
13
Arvinas
ARVN
$568M
| $12M | 2.6% | 178,500 | – | – |
|
|
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $10.5M | 2.27% | +100,000 | New | +$10.5M |
|
15
Century Therapeutics
IPSC
$42.5M
| $8.29M | 1.79% | 658,266 -44,357 | -6% | -$558K |
|
16
Immunovant
IMVT
$2.56B
| $8.13M | 1.76% | 1,475,000 +902,138 | +157% | +$4.97M |
|
|
SURF
17
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $6.76M | 1.46% | +2,300,000 | New | +$6.76M |
|
18
Avidity Biosciences
RNA
$5.99B
| $5.94M | 1.28% | 321,641 -125,000 | -28% | -$2.31M |
|
19
Dyne Therapeutics
DYN
$1.92B
| $5.06M | 1.09% | 525,284 -58,365 | -10% | -$563K |
|
20
SPDR S&P Biotech ETF
XBI
$5.07B
| $5.02M | 1.08% | +55,800 | New | +$5.02M |
|
|
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $3.02M | 0.65% | 80,000 -120,000 | -60% | -$4.53M |
|
|
OMGA
22
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $1.1M | 0.24% | 176,470 | – | – |
|
|
CNTB
23
Connect Biopharma
CNTB
$115M
| $845K | 0.18% | 279,921 | – | – |
|
|
AMAM
24
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $616K | 0.13% | 149,400 -187,468 | -56% | -$773K |
|
25
Compass Therapeutics
CMPX
$483M
| – | – | -240,000 | Closed | -$761K |
|